DEFINING TOMORROW'S VASCULAR STRATEGIES
×
Register now to R3i !
Become a member to receive our newsletter and get unrestricted access to downloadable slidekits...
Your login
Your password
Confirm your password
Your email
I agree to receive the R3i newsletter
The Initiative

Prof. Alberto Zambon

Prof. Alberto Zambon
University of Padova,
Padova, Italy
 
Current position
 
2000 - Affiliate Assistant Professor of Medicine - Division of Metabolism, Endocrinology, and Nutrition, University of Washington, Seattle, USA
1998 - Assistant Professor of Medicine - School of Medicine, Department of Medical and Surgical Sciences, Clinica Medica 1° - University of Padua, Italy
 
Past position
 
1999 Assistant Professor of Medicine - University of Washington, USA
2004 and 2006 Visiting scientist - Children’s Hospital Oakland Research Institute (CHORI), Lipid Laboratory, Oakland, CA, USA
 
Scientific training
 
1988 Graduated - University of Padua, Italy
1991 - 1995 Post-doctoral fellow - Division of Metabolism, Endocrinology and Nutrition of the University of Washington, Seattle, USA

Ph.D. in Gerontology - University of Padua, Italy
 
Professional Associations
 
1993 - Fellow and Silver Heart Member of the American Heart Association, Council on Arteriosclerosis, Thrombosis and Vascular Biology
1998 - Member of the Italian Society for the Study of Atherosclerosis (S.I.S.A.).
1998 - Member of the International Atherosclerosis Society (I.A.S.).
2003 - Member of the International Advisory Board of the Meeting on “Drugs  Affecting Lipid Metabolism”, DALM, Giovanni Lorenzini Foundation
2005 - Board of Speakers of the International Atherosclerosis Society Foundation
 
Awards
 
1996 - 1997 Fellowship award of American Heart Association
1998 The Paul Beeson Physician Faculty Scholarship by the American Federation For Ageing Research (AFAR)
2000 Young Investigator Award of the American Federation for Medical Research
2002 Award for Outstanding Scientific Contributions in Medical Research by the Scientific Committee at the School of Medicine, University of Padua.
 
Publications (selection)
  1. Zambon A, Hashimoto SI, Brunzell JD (1993). Analysis of techniques to obtain plasma for measurement of levels of free fatty acids. Journal of Lipid Research  (34): 1021-8
    [ISSN 0022-2275] PMID: 8354949 IF 4,159.
  2. Zambon A, Torres A, Bijvoet S, Gagne C, Moorjani S, Lupien PJ, Hayden MR, Brunzell JD (1993).
    Prevention of raised low-density lipoprotein cholesterol in a patient with familial hypercholesterolaemia and lipoprotein lipase deficiency. Lancet  (341): 1119-21
    [ISSN 0140-6736] PMID: 8097805 IF 21,713.
  3. Hokanson JE, Austin MA, Zambon A, Brunzell JD (1993). Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia. Arteriosclerosis Thrombosis and Vascular Biology (13): 427-34
    [ISSN 1079-5642] PMID: 8443147 IF 7,432.
  4. Zambon A, Austin MA, Brown BG, Hokanson JE, Brunzell JD (1993). Effect of hepatic lipase on LDL in normal men and those with coronary artery disease. Arteriosclerosis Thrombosis and Vascular Biology (13): 147-53
    [ISSN 1079-5642] PMID: 8427851 IF 7,432.
  5. Zambon A, Schmidt I, Beisiegel U, Brunzell JD (1997). Dimeric lipoprotein lipase is bound to triglyceride-rich plasma lipoproteins. Journal of Lidip Research (37): 2394-404
    [ISSN 0022-2275] PMID: 8978491 IF 4,159.
  6. Zambon A, Deeb SS, Hokanson JE, Brown BG, BrunzellL JD (1998).
    Common variants in the promoter of the hepatic lipase gene are associated with lower levels of hepatic lipase activity, buoyant LDL, and higher HDL2 cholesterol. Arteriosclerosis Thrombosis and Vascular Biology (18): 1723-9
    [ISSN 1079-5642] PMID: 9812910 IF 7,432.
  7. Zambon A, Hokanson JE (1998). Lipoprotein classes and coronary disease regression. Current Opinion in Lipidology  (9): 329-36
    [ISSN 0957-9672] PMID: 9739489 IF 6,232.
  8. Zambon A, Sartore G, Passera D, Francini-Pesenti F, Bassi A, Basso C, Zambon S, Manzato E, Crepaldi G (1999). Effects of hypocaloric dietary treatment enriched in oleic acid on LDL and HDL subclass distribution in mildly obese women. Journal of Internal Medicine  (246): 191-201
    [ISSN 0954-6820] PMID: 10447788 IF 3,59
  9. Zambon A, Hokanson JE, Brown BG, Brunzell JD (1999).
    Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation  (99): 1959-64
    [ISSN 0009-7322] PMID: 10208998 IF 12,563
  10. Zambon A, Deeb SS, Brown BG, Hokanson JE, BrunzellL JD (2001).
    Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.Circulation   (103): 792-8
    [ISSN 0009-7322] PMID: 11171785 IF 12,563.
  11. Zambon A, Brown BG, Deeb SS, BRrunzell JD (2001).
    Hepatic lipase as a focal point for the development and treatment of coronary artery disease. Journal of Investigative Medicine  (49): 112-8
    [ISSN 1081-5589] PMID: 11217140 IF 1,959.
  12. Zambon A, Deeb SS, Bensadoun A, Foster KE, Brunzell JD (2001).
    In vivo evidence of a role for hepatic lipase in human apoB-containing lipoprotein metabolism, independent of its lipolytic activity. Journal of Lipid Research  (41): 2094-9
    [ISSN 0022-2275] PMID: 11108744 IF 4,159
  13. Zambon A, Brown BG, Deeb SS, Brunzell JD (2001). Hepatic lipase as a focal point for coronary artery disease regression with lipid lowering therapy. Journal of Investigative Medicine   (49): 112-118
    [ISSN 1081-5589] PMID:  IF 1,959
  14. Zambon A, Bertocco S, Vitturi N, Polentarutti V, Vianello D, Crepaldi G (2003). Relevance of hepatic lipase to the metabolism of triacylglycerol-rich lipoproteins.Biochemical Society Transactions  (31): 1070-4
    [ISSN 0300-5127] PMID: 14505482 IF 2,267
  15. Zambon A, Deeb SS, Pauletto P, Crepaldi G, Brunzell JD (2003). Hepatic lipase: a marker for cardiovascular disease risk and response to therapy. Current Opinion in Lipidology  (14): 179-89
    [ISSN 0957-9672] PMID: 12642787 IF 6,232
  16. Zambon A, Pauletto P, Crepaldi G (2005). Review article: the metabolic syndrome--a chronic cardiovascular inflammatory condition. Alimentary Pharmacology & Therapeutics  (22 Suppl 2): 20-23
    [ISSN 0269-2813] PMID: 16225466
  17. Zambon A, Gervois P, Pauletto P, Fruchart JC, Staels B (2006). Modulation of Hepatic Inflammatory Risk Markers of Cardiovascular Diseases by PPAR-{alpha} Activators. Clinical and Experimental Evidence.
    Arteriosclerosis Thrombosis and Vascular Biology, 2006 May;26(5):977-86.
    [ISSN 1079-5642] PMID: 1642435
  18. Zambon A, Brown BG, Hokanson JE, Motulsky AG, Brunzell L JD (2006). Genetically determined apo B levels and peak LDL density predict angiographic response to intensive lipid-lowering therapy.
    Journal of Internal Medicine   (259): 401-9
    [ISSN 0954-6820] PMID: 16594908
  19. Zambon A, Brown BG, Deeb SS, BrunzellL JD (2006). Genetics of apolipoprotein B and apolipoprotein AI and premature coronary artery disease. Journal of Internal Medicine   (259): 473-80
    [ISSN 0954-6820 ] PMID: 16629853
  20. Zambon A, (2006). Reducing cardiovascular risk in the diabetic patient: implications from the FIELD study. Diabetes Vasc Dis. Res. (3, SUPPL. 1): S16-S20. PMID: 17935056
  21. Maggi S, Zambon A, Noale M, Gallina P, Bianchi D, Marzari C, Limongi F, Crepaldi G for the ILSA Working Group (2007). Validity of the ATP III diagnostic criteria for the Metabolic Syndrome in an elderly Caucasian population. The Italian Longitudinal Study on Aging. Atherosclerosis  2007, Sep. 10, EPUB AHEAD OF PRINT
    [ISSN 0021-9150 ] PMID: 16629853
  22. Zambon A, (2007). Type 2 diabetes patients: profiles, treatment and daily practice. Diabetes Vasc Dis. Res.. (4, SUPPL. 2): S12-S16. PMID: 17935056
  23. Zambon A, Cusi K (2007). The role of fenofibrate in clinical practice. Diabetes Vasc Dis. Res. (4 SUPPL 3):S15-20.  PMID: 17935056
 
Research
 
His current research projects focus on:
  • Mechanisms of atherosclerotic plaque progression and regression and particularly on the genetic background leading to lipoprotein abnormalities responsible for the unstable atherosclerotic plaque.
  • A second line of research focuses the common pathophysiological links between lipoprotein abnormalities specifically related to particle size and density, and endothelial dysfunction both as an early marker of atherosclerosis as well as a potential link between the atherosclerotic process and venous thromboembolism;
  • A third line of research deals with lipid oxidation and brain small vessel disease (endothelial dysfunction at cerebral site) as potential clinically relevant background for the development of Alzheimer’s Disease.
Dr. Zambon maintains several collaborative projects with the Division of Metabolism, Endocrinology and Nutrition (Chair Prof. A. Chait) and with the Division of Cardiology (Prof. B.G.  Brown) of the University of Washington, Seattle, USA, where he holds a position of Affiliate Assistant Professor.

Dr. Zambon is also collaborating with the  Children’s Hospital Oakland Research Institute (CHORI), Lipid Laboratory, Director Prof. Ron M. Krauss. Oakland, CA, USA, with the aim of implementing accurate and easily accessible techniques for the study of lipoprotein plasma mass distribution.